# Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

> **NCT00473577** · PHASE1 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 40 (estimated)

## Conditions studied

- Hematologic Neoplasms
- Neoplasms

## Interventions

- **DRUG:** CRA-24781

## Key facts

- **NCT ID:** NCT00473577
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-11
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473577, "Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00473577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*